<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704652</url>
  </required_header>
  <id_info>
    <org_study_id>394/2007</org_study_id>
    <nct_id>NCT00704652</nct_id>
  </id_info>
  <brief_title>Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus</brief_title>
  <acronym>EPOinDR</acronym>
  <official_title>Evaluation of Functional and Morphological Retinal Changes in the Course of Systemic Aranesp Treatment in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether systemic administration of darbepoetin
      alpha results in the progression or regression of diabetic macular edema.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient recruitment was not sufficient to achieve the needed patient numbers.
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Morphologic changes in the retina detected by HD-OCT following darbepoetin alpha therapy compared to control patients</measure>
    <time_frame>9 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional improvement in best corrected visual acuity (BCVA) and microperimetry following darbepoetin alpha therapy compared to control patients.</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in anterior chamber flare and cell count following darbepoetin alpha therapy compared to control patients.</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the fundus image and fluorescein angiographic features following darbepoetin alpha therapy compared to control patients.</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood count, chemistry, Astrup and blood clotting following darbepoetin alpha therapy compared to control patients.</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic patients with min. Grade 2 renal insufficiency, and in Group B with anemia that is
        to be treated with systemic ESA therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group A:

          -  Males and females aged 18 to 80 yrs

          -  Diabetes mellitus type 1 or 2

          -  Haemoglobin level above the treatment threshold level (as described in the drug
             description)

          -  Receiving no darbepoetin alfa treatment

          -  Best Corrected Visual Acuity (BCVA) better than 20/200

          -  No clinically significant macular edema (CSME) or CSME already treated with laser
             photocoagulation.

        Group B:

          -  Males and females aged 18 to 80 yrs

          -  Diabetes mellitus type 1 or2

          -  Anaemia (due to renal failure), haemoglobin level under the treatment threshold level
             before the initialisation of the therapy (as described in the drug label)

          -  Starting to receive darbepoetin alfa treatment (darbepoetin alfa, Aranesp, Amgen)

          -  BCVA better than 20/200

          -  No clinically significant macular edema (CSME) or CSME already treated with laser
             photocoagulation.

        Exclusion Criteria:

          -  History of retinal disease other than DR

          -  History of intraocular surgery, including laser treatment in the past 4 month

          -  A major change in the insulin treatment of the patient in the past 4 month or during
             the follow up period.

          -  Inability to communicate in German or English

          -  Dementia; inability to follow commands

          -  Epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ursula Schmidt-Erfurth, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departmen of Ophthalmology, Medical Unversity of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departmen of Ophthalmology, Medical Unversity of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gabor Deak</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

